Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00193973 | Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma | completed | Phase 2 | 20 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Feb 17, 2017 | clinicaltrials |
| NCT02435108 | A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy | completed | Phase 2 | 2 | Samsung Medical CenterOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT01475058 | CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant | completed | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00143065 | Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 8 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT00201682 | Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 36 | John ByrdOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT00790647 | Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis | completed | Phase 2 | 10 | Boston Medical CenterOTHER | 1 | Feb 6, 2017 | clinicaltrials |
| NCT00947856 | A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study | completed | Phase 2 | 110 | Seagen Inc.INDUSTRY | 2 | Feb 2, 2017 | clinicaltrials |
| NCT00633594 | Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 39 | SCRI Development Innovations, LLCOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT01029054 | Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma | completed | Phase 1 / Phase 2 | 53 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT00873093 | Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | completed | Phase 2 | 148 | National Cancer Institute (NCI)NIH | 4 | Jan 27, 2017 | clinicaltrials |
| NCT02169180 | Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma | completed | Phase 2 | 16 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Jan 24, 2017 | clinicaltrials |
| NCT01810120 | Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT | completed | Phase 1 / Phase 2 | 30 | Mariella EnocOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT00933335 | Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab | completed | Phase 2 | 38 | GlaxoSmithKlineINDUSTRY | 0 | Jan 18, 2017 | clinicaltrials |
| NCT00950755 | Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology | completed | Phase 2 | 41 | GlaxoSmithKlineINDUSTRY | 0 | Jan 18, 2017 | clinicaltrials |
| NCT01573000 | A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL) | completed | Phase 2 | 78 | GlaxoSmithKlineINDUSTRY | 0 | Jan 18, 2017 | clinicaltrials |
| NCT00931918 | Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients | completed | Phase 2 | 206 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 11, 2017 | clinicaltrials |
| NCT00996996 | Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma | completed | Phase 2 | 77 | GlaxoSmithKlineINDUSTRY | 0 | Jan 11, 2017 | clinicaltrials |
| NCT01663714 | Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma. | completed | Phase 2 | 30 | GlaxoSmithKlineINDUSTRY | 0 | Jan 11, 2017 | clinicaltrials |
| NCT00268203 | Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma | completed | Phase 2 | 765 | GlaxoSmithKlineINDUSTRY | 0 | Jan 9, 2017 | clinicaltrials |
| NCT00938041 | Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody | completed | Phase 2 | 32 | GlaxoSmithKlineINDUSTRY | 0 | Jan 9, 2017 | clinicaltrials |
| NCT01868035 | Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP | completed | Phase 2 | 15 | GlaxoSmithKlineINDUSTRY | 0 | Jan 9, 2017 | clinicaltrials |
| NCT01741792 | Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | completed | Phase 2 | 25 | Amgen Research (Munich) GmbHINDUSTRY | 1 | Jan 6, 2017 | clinicaltrials |
| NCT00684411 | Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 5, 2017 | clinicaltrials |
| NCT00099047 | Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Dec 30, 2016 | clinicaltrials |
| NCT01733953 | Statin Therapy in Young Adult Survivors of Childhood Cancer | completed | Phase 2 | 27 | University of MinnesotaOTHER | 1 | Dec 14, 2016 | clinicaltrials |
| NCT00989664 | Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 60 | GlaxoSmithKlineINDUSTRY | 0 | Dec 13, 2016 | clinicaltrials |
| NCT01224821 | Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies(RIT-II-001) | completed | Phase 2 | 47 | GlaxoSmithKlineINDUSTRY | 0 | Dec 12, 2016 | clinicaltrials |
| NCT00040937 | S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 147 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00306735 | Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation. | completed | Phase 2 | 75 | Eisai Inc.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT00611208 | A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 2 | 32 | Virogen Biotechnology Inc.INDUSTRY | 1 | Nov 29, 2016 | clinicaltrials |
| NCT01421667 | A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 176 | Seagen Inc.INDUSTRY | 2 | Nov 28, 2016 | clinicaltrials |
| NCT00996593 | Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab | completed | Phase 2 | 43 | GlaxoSmithKlineINDUSTRY | 0 | Nov 23, 2016 | clinicaltrials |
| NCT00378209 | Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 65 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 17, 2016 | clinicaltrials |
| NCT00656084 | Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell | completed | Phase 2 | 16 | US Oncology ResearchINDUSTRY | 0 | Nov 3, 2016 | clinicaltrials |
| NCT01388959 | A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 40 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01392716 | A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 48 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02011113 | Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 36 | Celgene CorporationINDUSTRY | 1 | Nov 1, 2016 | clinicaltrials |
| NCT00891618 | Acupuncture for Chemo-Induced Peripheral Neuropathy | completed | Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2016 | clinicaltrials |
| NCT00025662 | Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | completed | Phase 2 | 23 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Oct 28, 2016 | clinicaltrials |
| NCT00634179 | A Phase I/II Trial of VR-CHOP in Lymphoma Patients | completed | Phase 1 / Phase 2 | 37 | Emory UniversityOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT02471820 | Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients(RAD) | completed | Phase 2 | 45 | Meletios A. DimopoulosOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| NCT00779922 | Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function | completed | Phase 2 | 39 | Poitiers University HospitalOTHER | 1 | Oct 11, 2016 | clinicaltrials |
| NCT00862719 | Sitagliptin Umbilical Cord Blood Transplant Study | completed | Phase 2 | 29 | Indiana UniversityOTHER | 1 | Oct 7, 2016 | clinicaltrials |
| NCT00607854 | Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)(ZEVALLO) | completed | Phase 2 | 31 | University Hospital, BordeauxOTHER | 1 | Oct 5, 2016 | clinicaltrials |
| NCT00580372 | UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma | completed | Phase 2 | 231 | University of ArkansasOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT01113632 | Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 77 | SCRI Development Innovations, LLCOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT00798096 | Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma | completed | Phase 2 | 18 | Rigel PharmaceuticalsINDUSTRY | 2 | Sep 19, 2016 | clinicaltrials |
| NCT00800839 | Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide | completed | Phase 2 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Feb 17, 2017source: clinicaltrials